>PROKKA_00001 hypothetical protein
MGTRLKELSLIYKNNTLNEDDKKNIEYEAKSLLDNMYFTIKNTKFNGKNLFTGEKLNIQG
STYNTDIKLMDFKVPKEDSIFIGNNKSSNESHTIKISDTKIDVILKKYNLEKANKIIFYE
SEMVDKHNIKTVFTSKYGYKNNANIDIVNVSNNVNKMFSINGTINDNSEVKGYLQEEDNK
LIGNININDKEYNIQLETTMEYALKTNLNSIKTTIINKNNHTFRGNTSIVDIQDNSGMTY
TSKEITIYEFKEIIANNKSNNKNKQIVFELSNNKKITFDINNKDINLYIFDEEYNSFDIS
DILNSSNIIEEKVLSELNNYQNYIGIKTNELEYKLNFEQNNQIL*
>PROKKA_00002 Transposase
VAKKIYSTELKLEIVKKYLSDNVSFGMLAQECNINKEDIQKWFVVYREHGEAVLSTVNGT
YTRDFKINVVEHIHNCSD*
>PROKKA_00003 Hemagglutinin components HA-22/23/53 precursor
MNSSIKKIYNDIQEKVINYSDTIDLADGNYVVRRGDGWILSRQNQILGGSVISNGSTGIV
GDLRVNDNAIPYYYPTPSFNEEYIKNNIQTVFTNFTEANQIPIGFEFSKTAPSNKNLYMY
LQYTYIRYEIIKVLQHEIIERAVLYVPSLGYVKSIEFNPGEKINKDFYFLTNDKCILNEQ
FLYKKILETTKNIPTNNIFNSKVSSTQRVLPYSNGLYVINKGDGYIRTNDKDLIGTLLIE
AGSSGSIIQPRLRNTTRPLFTTSNDTKFSQQYTEERLKDAFNVQLFNTSTSLFKFVEEAP
SDKNICIKAYNTYEKYELIDYQNGSIVNKAEYYLPSLGYCEVTNAPSPESEVVKMQVAED
GFIQNGPEEEIVVGVIDPSENIQEINTAISDNYTYNIPGIVNNNPFYILFTVNTTGIYKI
NTQNNLPPLKIYEAIGSGNRNLQAGNLCNNNIKAINYITGVDDPNTKSYLVVLLNKDKNY
YIRVPQTSPNIENQIKFKREEGDLRNLMNSSVNIIDNLNSTGAHYYTRQSPDVGNYISYE
FTVPGNFNNKDTSNIRLYTSNNQGIGTLFRVIETIDGYKLIGIRQNLHLLNNTNSIRLLN
GAIYILKVEVTELNNYNIRLHIDITN*
>PROKKA_00004 HA 17 kDa subunit
MSVERTFLPNGNYNIKSIFSGSLYLNPVSKSLTFSNESSANNQKWNVEYMAENRCFKISN
VAEPNKYLSYDNFGFISLDSLSNRCYWFPIKIAVNTYIMLSLNKVNELDYAWDIYDTNEN
ILSQPLLLLPNFDIYNSNQMFKLEKI*
>PROKKA_00005 hypothetical protein
MEHYSVIQNSLNDKIVTISCKADTNLFFYQVAGNVSLFQQTRNYLERWRLIYDSNKAAYK
IKSMDIHNTNLVLTWNAPTHNISTQQDSNADNQYWLLLKDIGNNSFIIASYKNPNLVLYA
DTVARNLKLSTLNNSNYIKFIIEDYIISDLNNFTCKISPILDRNKVVQQVDMTNLNVNLY
TWDYGRNQKWTIRYNEEKAAYQFFNTILSNGVLTWIFSNGNTVRVSSSNDQNNDAQYWLI
NPVSDTDETYTITNLRDTTKALDLYNSQTANGTAIQVFNYHGDDNQKWNIRNP*
>PROKKA_00006 transcriptional regulator BotR, P-21
MNKLFLQIKMLKNDNEEFQEIFKHFEKTINIFTRKYNIYDNYNDILYHLWYTLKKVDLSN
FNTQNDLERYISRTLKRYCLDICNKRKIDKKIIYNSEIADKKLSLIANSYSSYSEFEFND
LISILPDDQKKIIYMKFVEDIKEIDIAKKLNISRQSVYKNKIMALERLEPILKKLINM*
>PROKKA_00007 Botulinum neurotoxin type A precursor
MCVEINLGEWLDMNINDNLSINSPVDNKNVVVVRARKTDTVFKAFKVAPNIWVAPERYYG
ESLSIDEEYKVDGGIYDSNFLSQDSEKDKFLQAIITLLKRINSTNAGEKLLSLISTAIPF
PYGYIGGGYYAPNMITFGSAPKSNKKLNSLISSTIPFPYAGYRETNYLSSEDNKSFYASN
IVIFGPGANIVENNTVFYKKEDAENGMGTMTEIWFQPFLTYKYDEFYIDPAIELIKCLIK
SLYFLYGIKPSDDLVIPYRLRSELENIEYSQLNIVDLLVSGGIDPKFINTDPYWFIDNYF
SNAKKVFEDHRNIYETEIEGNNAIGNDIKLRLKQKFRININDIWELNLNYFSKEFSIMMP
DRFNNALKHFYRKQYYKIDYPENYSINGFVNGQINAQLSLSDRNQDIINKPEEIINLLNG
NNVSLMRSNIYGDGLKSTVDDFYSNYKIPYNRAYEYHFNNSNDSSLDNVNIGVIDNIPEI
IDVNPYKENCDKFSPVQKITSTREINTNIPWPINYLQAQNTNNEKFSLSSDFVEVVSSKD
KSLVYSFLSNVMFYLDSIKDNSPIDTDKKYYLWLREIFRNYSFDITATQEINTDCGINKV
VTWFGKALNILNTSDSFVEEFQNLGPISLINKKENLSMPKIEIDEIPNSMLNLSFKDLSE
NLFNIFSKNNSYFEKIYYDFLDQWWTQYYSQYFDLICMAKRSVLAQESLIKKIIQKKLSY
LIGNSNISSDNLALMNLTTTNTLRDISNESQIAMNNVNNFLNNVAICVFQTNIYPKFISF
MEQCINNINKNTREFIQKCTNITENEKLQLINQNIFSSLDFDFLNIENLKSLFNSETGLL
IKEETSPYELVLYAFQEPGNNAIGDASGKNTSIEYSKDIGLVYGINSDALYLNGSNQSIS
FSNDFFENGLTNSFSIYFWLRNLGKDTIKSKLIGSKEDNCGWEIYFQDTGLVFNMIDSNG
NEKNIYLSDVSNNSWHYITISVDRLKEQLLIFIDDNLVANESIKEILNIYSSNTISLVNE
NNPIYVEGLSILNKPTTSQEVLSNYFKVLNNSYIRDSSEERLEYNKTYQLYNYVFSENPI
YEIKQNNNIYLTINNTNNLNLQVSKFKLLSINPNKQYVQKLDEVIISVLDNMEKYIDISE
DNRLQLIDNKNNAKKMIISNDIFISNCLIISYNGKYICLSMKDENHNWMICNNDMSKYLY
LWSFK*
>PROKKA_00008 Botulinum neurotoxin type A precursor
MQFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL*
>PROKKA_00009 hypothetical protein
MLISSYFNLFNIITVRKNTIFIVNTSLVVYLINDTRYHYNDFANYSFE*
>PROKKA_00010 Autolytic lysozyme
MLKGIDVSEHQGEIGWKAVKNSGIQFAILRAGYGKNNIDKQFINNANGCTSVGMPFGLYW
FSYAYTENMARKEAQYCVAQAKKYKISYPICYDLEYDTIRYANNCGVTITKSLATKMVHA
FCQEVERNGYFAMNYSNQDFLLNKFDSNLLKRYALWYAWYNNSLNRTCGIWQYSENGRVP
GIAGAAVDMNYCYLNMPGASNTSPNKNAFRGVHYLIRELQQEINSQGLGEVVVDGIAGQA
TINSAPVCKQGARGGITKVIQQMLISIGYPVGSHGVDGVFGDSTVTAIKAFQRDCHLVAD
GIVGKETWKALFRNLK*
>PROKKA_00011 hypothetical protein
MKTIRFKIVAGINEGYFHENENKNRIQIVGV*
>PROKKA_00012 Nucleoside 2-deoxyribosyltransferase
MSKRVFLAAPFKGVIKEKQSIMKEQEKKRIENLILFLEEKGWKVDNAHKREAWGANFMSP
DQCTKLDYDAIKECDLFIAFPGVPVSPGTHIEIGWASAMDKKIILLLAEKEENYAYLIRG
LHTVSNVHYIIYNEEKEYLQKLDLYLDGENNEV*
>PROKKA_00013 Thymidylate synthase 2
MKFKNFHEAYLKNLNDVYYTPEFINQPRGNVSKERLNYFMILENPRERICYTKSRKTNIV
FNFAEALWYLSGSNDLDYISYYASNMKKYSMDGKTLTGTAYGPKIFSYGHNNANQWHRIV
ELFKEDPDTKRGFIEIFDANEDLSLKNIDVSCTIGFQFFIREHKLYMTTFMRANDAYRGI
ISDVFSFTFIQEFLATELNLDIGQYSHQVATTHIYEPDFKLAEKVLCESKSVKKELSFPR
MPKKDNWEDLKIVLQYEKELRKQRIHLTKKDIDELEIDKYWKQIICLFVLYQEIYYEDNL
DYEIYESLEPLYQYLFSNKWNQYF*
>PROKKA_00014 ubiquinone/menaquinone biosynthesis methyltransferase
MESIFLGGNILGTCWKDEGVSKKFNLYNDMLENILGFDYIFENLKSNESIKKILDFGCGP
GKVAERMAKIKPESQIIAVDQSQNMLDIAMKEHNKENIDYKLIEQNQLKEIEKNSIDCVV
LCFVIINNSDKDRIKTIFQEIFRVLKKGRKFFILDSNPNAAGVEFSTFTNGKSGQAYHLG
DHKKQFLKIPNNEVLILEDYYWPIDFYINNLEAVGFENYKIVEPTIEKINKPDLNAIEKT
YDIECWGSEKNKPPFIIFDVEK*
>PROKKA_00015 Thiaminase-1 precursor
MKLKNLFKRSLSLLFSFIMIFTLVSGLNVKAFSGDEPKQTLNVALYEYVPDPIRFKKAVE
TEWNKKEPNIKLNFVDWDCYSEDPPKDLDVFVFDAIYLSHFVKEGYLSEIPEKDIKNKED
ILPFAMEGCTIKGSAYAIPQIICTNLLFSRKGDSDIQNINSVFDLNDKLGKNTSEDIIPP
ENKGLLIDMSGGTSKACMYLDSLIDTTQEYTKFCSLPNLNELNKDAIESLVLLQSMAGKS
QANYWPENNDSYIRAKWFINGKGRAYIGYTEAMSQMKEFANDIDFKTISLSKNSNIPIFY
GDVAGINSSITNSYKKEKAIELANIITDKNTMVNAVSPDENNKYPQYLLPARRSVYHNLE
NKYPIYGKLYKIADNSNNKLFRTGPEIREWLKQAKKIITEYLQQ*
>PROKKA_00016 Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase
MKKVLSIAGSDCSGGAGIQADLKTFSAHGVFGMSVIVSVVAENTSRVIDIQDVTPDMIKS
QIDAVYEDIGTDAVKIGMLSTPDCMKAVSEKLQEYKPKNVVIDPVMYAKNGCPLMDPNSV
STLIQSIIYHADILTPNIPEAERISGYKIKTLEDMEKAAGIIEGMGCKSVLIKGGHYIGD
AVDVLYDGNKFYHYKTQRIHTKNTHGTGCTLSSAIASNLALGFEINEAVKRAKNYITMAI
EHSLEIGKGNGPTNHFYQVYLNGLKGMELDNHTRS*
>PROKKA_00017 hypothetical protein
MRKVYKNPKELATCLKDLVDLYFEDLMTYEKLEEKVSKIVEANKDSIYKNGVINTKLANV
LGDLRIDVINKIVKEK*
>PROKKA_00018 putative membrane protein
MTKYAIVFFMSMVPIVELRGAIPYSQMYNLPLLQSFIVAIIGNMLPMPFIYLFARKVLVW
GADKPITGKFFTWCLEKGEKAGKKLQEKTGKKGLFWGLLIFVAIPAPGTGAWTGTLAASL
LDMDFKTSILAVMLGVLVAGIIMGTASVGLFSFF*
>PROKKA_00019 putative ABC transporter ATP-binding protein YxlF
MDKPNDVVVSIRNLKMSYGSKEVLKGINLDVNKGEIIGYIGPNGAGKSTTVKIMLGLVKG
YEGEVKIFGNNISYENVEYKHKIGYVPENGEIYDNLTAYEYITFLGEIYGMELKEVNNKA
KKLMSLFGIKEAYHSRISSYSKGMRQKLLIISSLIHNPDILFLDESLSGLDANSVLVFKE
VLSKLASEGKTIFYSSHIMEVVEKISSRIILLNNGQIAADGTFEELKKKNMEGSLEQIFN
QITGFTKHEEIANEFISILKEV*
>PROKKA_00020 hypothetical protein
MIKNIMAPIFILIFTIIGDGIKIKTARKTPINPYRNSDFLKVFFLFSFSLSLYIVGTLLL
SIKSFNLSIVLMEA*
